Literature DB >> 12649517

Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke.

Joan Montaner1, Marc Ribó, Jasone Monasterio, Carlos A Molina, José Alvarez-Sabín.   

Abstract

BACKGROUND AND
PURPOSE: Thrombin-activable fibrinolysis inhibitor (TAFI) is a recently identified fibrinolysis inhibitor in plasma. The purpose of this work was to study TAFI levels in the acute phase of ischemic stroke and their relationship with stroke evolution.
METHODS: In 30 consecutive ischemic stroke patients, TAFI plasma levels were measured by means of enzyme-linked immunosorbent assay (percentage of the pooled reference kit expressed as mean+/-SD) and compared with the values obtained in 30 healthy control subjects. All samples were drawn within the first 24 hours after symptom onset (mean, 4.6 hours) and before any treatment was started.
RESULTS: TAFI plasma concentration was significantly higher (P<0.001) in stroke patients (158.4+/-53.2%) than in healthy control subjects (105.6+/-30.2%). The highest TAFI levels were found in cases of neurological deterioration (worsening, 198.1+/-63.0%; stability, 130.5+/-39.3%; improvement, 173.9+/-52.0%; P=0.057).
CONCLUSIONS: High levels of TAFI are found in the acute phase of ischemic stroke.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649517     DOI: 10.1161/01.STR.0000063139.06585.45

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

1.  Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.

Authors:  Xinkang Wang; Patricia L Smith; Mei-Yin Hsu; Joseph A Tamasi; Eileen Bird; William A Schumacher
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

2.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; Irfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-10-29       Impact factor: 3.633

3.  A genome-wide exploration suggests an oligogenic model of inheritance for the TAFI activity and its antigen levels.

Authors:  Maria Sabater-Lleal; Alfonso Buil; Juan Carlos Souto; Laura Alamsy; Montserrat Borrell; Mark Lathrop; John Blangero; Jordi Fontcuberta; José Manuel Soria
Journal:  Hum Genet       Date:  2008-06-18       Impact factor: 4.132

4.  Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.

Authors:  Peter Kraft; Tobias Schwarz; Joost C M Meijers; Guido Stoll; Christoph Kleinschnitz
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

5.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.

Authors:  Cihangir Erem; Ozge Ucuncu; Mustafa Yilmaz; Mustafa Kocak; İrfan Nuhoglu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

6.  Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.

Authors:  Cihangir Erem; Irfan Nuhoglu; Mustafa Kocak; Mustafa Yilmaz; Safiye Tuba Sipahi; Ozge Ucuncu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

7.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

8.  Molecular biomarkers in stroke diagnosis and prognosis.

Authors:  Matthew B Maas; Karen L Furie
Journal:  Biomark Med       Date:  2009-08-01       Impact factor: 2.851

9.  Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.

Authors:  C Nafría; I Fernández-Cadenas; M Mendioroz; S Domingues-Montanari; M Hernández-Guillamón; J Fernández-Morales; A Del Río-Espínola; D Giralt; L Deu; P Delgado; A Rosell; J Montaner
Journal:  Stroke Res Treat       Date:  2011-06-09

10.  Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.

Authors:  Bülent Alioğlu; Nevin Kılıç; Enver Şimşek; Yıldız Dallar
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.